About: Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: How Close Are We?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: How Close Are We? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: How Close Are We?
Creator	Memish, Ziad Omrani, Ali Address,
source	Medline; PMC
abstract	Over 1100 cases of MERS-CoV have been reported since it was first identified in June 2012. Clinical presentation ranges from asymptomatic or mild illness to rapidly progressive disease with multi-organ failure and high mortality. Treatment has been largely supportive. A large number of compounds have been shown to have significant in vitro inhibitory activity against MERS-CoV. Until recently, macaques were the only suitable animal models for animal studies, hindering further clinical development of MERS-CoV therapy. However, the recent successful development of MERS-CoV infection model in transduced mice offers opportunities to accelerate clinical development of therapeutic agents for MERS-CoV infection. Currently available evidence supports further clinical investigation of interferon-based treatment regimens for patients with MERS-CoV. Combining interferon with mycophenolate and/or high-dose ribavirin appears especially promising. Monoclonal antibodies against various targets within MERS-CoV Spike protein have yielded encouraging in-vitro results. However, their safety and efficacy require confirmation in animal models and exploratory clinical trials.
has issue date	2015-06-12(xsd:dateTime)
bibo:doi	10.1007/s40506-015-0048-2
bibo:pmid	32226324
has license	no-cc
sha1sum (hex)	3b63175c36af979e90f7815edc442b1b1816601b
schema:url	https://doi.org/10.1007/s40506-015-0048-2
resource representing a document's title	Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: How Close Are We?
has PubMed Central identifier	PMC7100761
has PubMed identifier	32226324
schema:publication	Curr Treat Options Infect Dis
resource representing a document's body	covid:3b63175c36af979e90f7815edc442b1b1816601b#body_text
is schema:about of	named entity 'OPTIONS' named entity 'HOW' named entity 'INTERFERON ' named entity 'THEIR' named entity 'CLINICAL PRESENTATION' named entity 'SUITABLE' named entity 'LARGELY' named entity 'VARIOUS' named entity 'NUMBER OF' named entity 'RESULTS' named entity 'EVIDENCE' named entity 'INFECTION MODEL' named entity 'SUCCESSFUL' named entity 'CASES' named entity 'SIGNIFICANT' named entity 'SAFETY' named entity 'HIGH' named entity 'RIBAVIRIN' named entity 'MILD' named entity 'RAPIDLY PROGRESSIVE' named entity 'SPIKE PROTEIN' named entity 'MACAQUES' named entity 'INFECTION' named entity 'TARGETS' named entity 'ACCELERATE' named entity 'MORTALITY' named entity 'PROTEIN ' named entity 'THERAPEUTIC AGENTS' named entity 'IDENTIFIED' named entity 'ASYMPTOMATIC' named entity 'INFECTION' named entity 'MONOCLONAL ANTIBODIES' named entity 'ANIMAL STUDIES' named entity 'THERAPY' named entity 'THERAPEUTIC' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'HIGH-DOSE' named entity '1100' named entity 'REPORTED' named entity 'LARGE' named entity 'TREATMENT' named entity 'DEVELOPMENT' named entity 'HAVE' named entity 'CLOSE' named entity 'CONFIRMATION' named entity 'EFFICACY' named entity 'COMBINING' named entity 'SUPPORTIVE' named entity 'JUNE' named entity 'MERS-COV' named entity 'MICE' named entity 'PATIENTS' named entity 'IN VITRO' named entity 'REGIMENS' named entity 'ANIMAL MODELS ' named entity 'MYCOPHENOLATE' named entity 'RECENT' named entity 'IN-VITRO' named entity 'AVAILABLE' named entity 'ILLNESS' named entity 'CLINICAL DEVELOPMENT' named entity 'CLINICAL TRIALS' named entity 'RECENTLY' named entity 'INHIBITORY ACTIVITY' named entity 'CURRENTLY' named entity 'PROGRESSIVE DISEASE' named entity 'MULTI-ORGAN FAILURE' named entity 'CLINICAL INVESTIGATION' covid:arg/3b63175c36af979e90f7815edc442b1b1816601b named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'progressive disease' named entity 'MERS-CoV' named entity 'infection' named entity 'animal models' named entity 'clinical trials' named entity 'mycophenolate' named entity 'transduced' named entity 'Infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software